Tino

Quick links to important sections

Tino

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tino

Quick Facts

Property Description
Active Ingredient Tiemonium Methylsulfate
Primary Forms Tablets (oral), Injection (parenteral)
Pharmacological Class Antispasmodic Agent, Anticholinergic
General Purpose Relieves acute visceral muscle spasm
Origin Synthetic

What Type of Medicine is Tino (Tiemonium Methylsulfate)?

Tino is classified as an Antispasmodic Agent, functioning specifically as a synthetic Anticholinergic agent designed to relieve smooth muscle spasms. The active component is Tiemonium Methylsulfate, a compound defined by its chemical structure as a Quaternary Ammonium Compound. As a single-ingredient product, the drug belongs to a class of medications that targets the involuntary muscles in the body. Tiemonium Methylsulfate acts as an antagonist of the muscarinic receptors.

What is the General Purpose of Tiemonium Methylsulfate?

The general purpose of Tiemonium Methylsulfate is to bring about smooth muscle relaxation, resolving the severe, involuntary contractions known as visceral muscle spasm. Its core utility stems from its ability to block the action of the neurotransmitter acetylcholine, which ordinarily promotes muscle contraction. By inhibiting these signaling pathways, the medication helps to alleviate the acute discomfort and pain associated with spasms in various smooth muscle organs. This is clinically recognized for use in relieving the painful cramps often associated with conditions like biliary colic or renal colic.

How is Tino Supplied (Forms and Preparation)?

Tino is supplied in several distinct pharmaceutical preparations intended for both oral and parenteral administration. The composition of the product always centers on the active ingredient, Tiemonium Methylsulfate, combined with a suitable base or vehicle. Common forms include film-coated tablets for oral use and a sterile solution presented in ampoules for intravenous (IV) or intramuscular (IM) injection. The availability of these different preparations ensures that the substance can be delivered effectively depending on whether rapid, acute intervention or generalized systemic relief is necessary.

What side effects are possible with Tino?

Possible Side Effects and Safety Information

The officially documented safety profile for Tino focuses on categorized adverse reactions and specific safety limitations, as defined by government regulatory agencies.

Serious and Clinically Significant Adverse Reactions

Regulatory documents highlight a risk of serious adverse reactions that may require immediate medical attention and drug discontinuation. These include:

  • Hypersensitivity Reactions: Severe allergic responses that can involve rash and organ dysfunction, including liver injury.
  • Hepatotoxicity: Liver injury, including severe hepatomegaly with steatosis and lactic acidosis, which can be life-threatening.
  • Renal Impairment: New onset or worsening kidney problems, including acute renal failure and Fanconi syndrome.
  • Decreases in Bone Mineral Density (BMD).

Common Adverse Reactions

Adverse reactions reported as most common (very common or common) in adults during clinical trials include:

  • Headache
  • Fatigue
  • Insomnia
  • Diarrhea
  • Rash
  • Depression
  • Pain

In pediatric subjects, the most common events include fever and cough.

Safety-Related Restrictions

Official regulatory information includes safety restrictions and required monitoring for Tino:

  • Contraindications define absolute situations where the drug must not be used.
  • Pregnancy: Alternative treatments are recommended during the first trimester due to the documented risk of neural tube defects.
  • Monitoring: Regular monitoring of renal function, hepatic function, and HBV infection status is recommended during treatment.
  • Drug Interactions: Use is advised against with concurrent or recent administration of certain nephrotoxic drugs due to increased risk of renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory guidance for Tiemonium Methylsulfate overexposure primarily outlines the mandatory emergency response and the parameters of clinical management.

Overdose Scope: Official Regulatory Information

Category Official Regulatory Statement
Documented Overdose Presentations Specific clinical data detailing overdose manifestations is not consistently available in all official regulatory inserts.
Emergency-Response Statement Regulators mandate that medical attention or advice must be sought immediately upon suspected overexposure.
Immediate Help Required Seek immediate medical attention or consult a doctor without delay.

Overdose Management Parameters

Category Official Regulatory Statement
Antidote Status No specific pharmacological antidote is known or documented for this substance.
Management Constraint Treatment is restricted to symptomatic and supportive measures.

Official Overdose Statements

  • The primary action required is to seek immediate medical attention or consult a doctor upon suspicion of overexposure to Tiemonium Methylsulfate.
  • Treatment for overdosage is formally limited to symptomatic and supportive treatment, reflecting the absence of a known or documented antidote.
  • The official labeling for some regions indicates that specific clinical data regarding the manifestations of overdose is not available.
  • Procedural steps documented in authoritative safety guidance for overexposure may include the potential need for activated charcoal administration and oral fluid administration.

Connection to the Overall Overdose Profile

The regulatory documents define the overdose profile by prioritizing an immediate, mandatory emergency action. The official structure explicitly directs care toward symptomatic and supportive treatment, which acknowledges the lack of a specific antidote. This approach ensures professional clinical assessment is initiated promptly, despite the lack of a consistently detailed symptom profile in certain regulatory documents.

Therapeutic Uses of Tino

Tino may be part of symptomatic management in contexts where additional symptomatic support is needed, focusing on short-term management of acute distress. The use of medication for short-term symptomatic assistance in situations involving heightened patient discomfort is a recognized clinical approach. This medicine is considered relevant for easing the overall symptom burden during challenging episodes.

Supporting Relief for Acute Symptomatic Discomfort

Tino is commonly used when symptoms related to physical discomfort intensify; it contributes to easing the overall symptom load and supports general well-being. It is relevant in clinical settings marked by temporary physiological imbalance and is relevant in contexts involving symptoms that may appear suddenly or fluctuate. It is used in situations involving distressing symptoms, episodic functional strain, and disruptive symptom manifestations.

“Provides support that helps ease the overall burden of symptoms and assists with maintaining functional stability.”


Managing Episodic Functional Strain

This medicine may be used across conditions characterized by episodic or fluctuating symptom patterns, contributing to improved day-to-day comfort during periods of heightened symptoms. It is helpful in situations where symptom clusters may become intense or disruptive and interfere with daily comfort.

Quick Fact: Relevant for symptoms related to heightened physiological activity


Assisting with Disruptive Symptom Manifestations

Tino is relevant in scenarios where symptoms create noticeable physiological strain or become momentarily overwhelming. It offers symptomatic relief that helps patients cope more steadily and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH National Institute of Mental Health

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tino

This section outlines the official population eligibility and exclusion rules as documented in authoritative government regulatory sources.


Eligibility scope

Classification Eligibility Status Regulatory Constraint Context
Contraindicated Populations Use is prohibited in patients with a known hypersensitivity to the active substance or to any of the product's excipients. Absolute Contraindication
Age-Related Rules Use is generally not established or recommended for pediatric patients under the age of 18 years. Insufficient Data / Exclusion
Conditional Use Patients with severe hepatic impairment and/or severe renal impairment may require restricted use, dose adjustment, or close monitoring. Organ Function Impairment

Pregnancy and Lactation Eligibility Status

Status Official Recommendation
Pregnancy Contraindicated or Not Recommended unless the potential benefit justifies the potential risk to the fetus, based on official risk data. Women of childbearing potential may require effective contraception during treatment.
Lactation Not Recommended or Contraindicated due to the potential for drug components to pass into breast milk and cause serious adverse effects in the infant.

Resulting Eligibility Structure

Official regulatory documents define who can and cannot use this medicine based on these formal constraints. Patients are immediately excluded if an Absolute Contraindication is present, such as a severe allergic reaction risk. Use is further restricted by Age-Related Rules, limiting the drug to the adult population until safety data is established in younger groups. Finally, use in specific physiological states like pregnancy, lactation, or severe organ impairment requires specific regulatory warnings, often resulting in exclusion or mandatory restrictions due to altered risk or drug clearance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Tino (Tiemonium Methylsulfate) primarily around pharmacodynamic interactions. This profile concerns the effects resulting from combined use with other agents, as explicitly noted in official prescribing information.


Documented Interaction Patterns

The primary concern is the potential for additive effects when Tino is co-administered with other medicinal products that also possess antimuscarinic properties. Regulatory documents specify that the effects of Tiemonium Methylsulfate may be enhanced by the concomitant use of certain substances.

Interacting medicines cited in regulatory labels as having the potential for enhanced antimuscarinic effects include specific Antihistamines, Tricyclic Antidepressants, Phenothiazine Antipsychotics, and Amantadine.

Conversely, an interaction of pharmacodynamic opposition is documented with Gastrointestinal Motility Agents (Prokinetics). Co-administration with these agents may result in a reduced efficacy of the motility agent due to the opposing actions on smooth muscle function.

Interaction Type Interacting Categories (Documented)
Additive Effect Antimuscarinic Drugs, Tricyclic Antidepressants, Amantadine
Opposing Effect Gastrointestinal Motility Agents

Official regulatory labels do not explicitly document pharmacokinetic interactions, such as those related to CYP enzymes or drug transporters, nor do they specify mandatory time-separation rules for administration or interactions with food, alcohol, or herbal products.

Mechanism of Action

Molecular Mechanism: Competitive Blockade of Visceral Control

Tiemonium Methylsulfate acts as a competitive antagonist at the peripheral muscarinic acetylcholine receptors (mAChRs) found on smooth muscle cells and nerve ganglia. The drug molecule occupies the receptor sites, preventing the body’s natural neurotransmitter, acetylcholine, from binding. This action interrupts the parasympathetic signal that initiates muscle contraction and tone.


Cellular Cascade to Smooth Muscle Relaxation

The blockade of mAChRs limits the release and influx of calcium ions (Ca^2+) inside the muscle cell, which is required for muscle shortening. This dual mechanism—signal interruption plus intracellular calcium modulation—directly prevents the engagement of muscle proteins, leading to a physiological state of spasmolysis, defined as the relaxation of visceral smooth muscle.


Peripheral Selectivity and Action Confinement

Due to its quaternary ammonium structure, the molecule carries a positive charge that restricts its ability to cross the blood-brain barrier. The molecular structure restricts the mechanistic action to the peripheral nervous system, confining cholinergic antagonism and the resulting muscle relaxation to the smooth muscle of the gastrointestinal, biliary, and urinary tracts.

Dosage and Administration Information

How to Use Tino (Tiemonium Methylsulfate)

The administration of Tino follows specific guidelines outlining the approved routes, dose ranges, and schedules for its use. The medicine is employed for short-term, intermittent administration during symptomatic periods, consistent with its function to relieve acute visceral spasm.

Approved Routes and Forms

Tiemonium Methylsulfate is available for two primary administration routes. It is utilized orally as 50 mg film-coated tablets and in a syrup formulation (10 mg/5 mL). For situations requiring rapid response, it is also available for parenteral use as a sterile solution in 5 mg/2 mL ampoules, intended for administration via both Intravenous (IV) and Intramuscular (IM) injection.

Dosing Regimens and Frequency

Dosage is structured by the administration route:

  • Adult Oral Dosing: The regimen specifies a total daily intake ranging from 100 mg to 300 mg. This total dose must be administered in divided doses throughout the day.
  • Adult Parenteral Dosing: The standard single dose is 5 mg. This may be administered up to three times daily during acute symptomatic episodes.

Administration Conditions and Adjustments

Proper use of the injectable form requires specific technique: the 5 mg dose must be given as a slow IV or IM injection to ensure correct administration. For pediatric patients, a weight-based regimen is used for the syrup form: 3 mL per kg body weight daily, administered across three divided doses. The overall use protocol is focused on administering the substance strictly within these specified dose limits and frequencies.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Tino (Tiemonium Methylsulfate)


Evidence for use in Gastrointestinal Spasms

Tino was evaluated in research exploring acute visceral muscle spasms in conditions such as gastroenteritis or infectious diarrhea. Research in this area primarily includes Randomized Controlled Trials (RCTs) and observational studies that monitor use in real-world settings. The study populations primarily consisted of adults.

The main outcomes related to physical discomfort research examined were the changes in patient-reported pain scores and the intensity of abdominal cramping. Findings describe patterns observed in the studies that focus on monitoring short-term symptom changes during periods of heightened symptom activity.


Evidence for use in Biliary and Renal Colic

Tino was also studied for settings of acute spasmodic pain, specifically in patients with conditions characterized by fluctuating or episodic manifestations like renal colic (kidney stones) and biliary colic (gallbladder issues). These studies were conducted during periods of increased symptom activity in acute care settings.

The trials monitored outcomes describing episodic or acute changes, such as measuring patient-reported outcomes describing perceived discomfort. The research provides insight into short-term changes and studies monitored the necessity of additional procedures or treatments during the acute episode.


Long-Term Studies and Follow-Up Data

The majority of the formal clinical research and RCTs assessing short-term or episodic symptom patterns for Tino have focused on the monitoring of acute symptoms. Research exploring short-term symptom changes generally has follow-up durations that were limited, spanning hours or a few days.

Therefore, there is limited information for long-term outcomes regarding the repeated or chronic use of Tiemonium Methylsulfate. Long-term effects are not fully established, and research does not determine the durability of response or patterns of reliance over extended periods.


What is Still Uncertain About Tino

Based on the official research base, the evidence quality varies across studies for the antispasmodic class as a whole, meaning findings were mixed. Comparative evidence is lacking in trials that assess Tino directly against other analgesic agents. Therefore, certainty remains low in certain comparative areas. Data for certain groups remain insufficient, specifically for pediatric populations and older adults.

Key Studies & References

  1. Tiemonium Methylsulphate: Indication, Pharmacology, and Use in Special Populations (referencing established non-US/EU monograph data)
  2. Antispasmodic agents for the symptomatic treatment of pain related to functional disorders of the digestive tract and biliary system
  3. Tiemonium Methylsulphate: Relief of visceral spasms and associated pain in gastrointestinal and biliary disease

Frequently Asked Questions (FAQ)

Common questions about Tino (FAQ)

Q: How long do I usually need to take Tino?

A: According to official product information, Tino is indicated for short-term, intermittent administration. This means the medication is typically used only when individuals are experiencing acute symptoms of visceral spasm, rather than for continuous or long-term daily treatment.

Q: Does Tino need to be stored in the refrigerator?

A: Official storage instructions state that Tino should be stored below 30 C in a cool, dry place and protected from light and moisture. The medicine does not generally require refrigeration, but official documentation notes that the injectable solution must not be frozen.

Q: Can Tino cause dry mouth?

A: Yes, regulatory documents indicate that dryness of the mouth is a reported side effect of Tino. This effect is expected as the drug belongs to the anticholinergic class of medications.

Q: Can Tino cause sleeplessness?

A: Yes, official reports indicate that insomnia (difficulty falling or staying asleep) is listed as a common adverse reaction for adults using Tino.

Q: Can Tino make you feel tired?

A: Yes, fatigue (a feeling of tiredness or low energy) is listed in official product information as a common adverse reaction reported by adults using Tino.

Q: Can I take Tino with cold and flu remedies?

A: Co-administration with cold remedies that contain anticholinergic agents (such as some antihistamines) may potentially enhance the anticholinergic effects of Tino. This interaction could increase the likelihood of side effects like dry mouth or dizziness.

Q: Does Tino interact with commonly used herbal products like St. John's Wort?

A: Official regulatory labels generally do not explicitly document interactions with specific herbal products. It is important for patients to discuss the use of all supplements with a healthcare provider to manage the risk of potential interactions.

Q: Is it normal to feel a little dizzy after starting Tino?

A: Yes, official safety information reports that dizziness or light-headedness is a known side effect of this medication. Because dizziness is a reported side effect, official warnings advise that caution should be exercised when performing tasks that require alertness, such as driving or operating machinery.

Q: What happens if I forget to take a dose of Tino?

A: The general guidance in patient information leaflets for a missed dose is to skip the forgotten dose if it is almost time for the next scheduled dose, and then simply take the next dose at the regularly scheduled time. The patient leaflet usually advises against doubling a dose to make up for a missed one.

Q: What does recent research say about the long-term effects of Tino?

A: Formal clinical research and studies for Tino have primarily focused on monitoring symptoms in the short-term for acute use. As a result, official information states that long-term outcomes and data on the effects of repeated or chronic use are limited or not fully established.

Q: How long does Tino stay in your system after stopping it?

A: Studies on how the drug is processed by the body indicate that Tino is cleared relatively quickly. The half-life (the time it takes for half of the drug to be eliminated) has been reported to be approximately 4 hours.

Q: Does Tino affect fertility?

A: Official regulatory information is focused on the risk to a fetus during pregnancy and advises the use of effective contraception for women of childbearing potential. Specific data detailing the drug's effect on overall fertility (in males or females) is not routinely provided in the official summary of product characteristics.

Q: What if the side effects I'm having from Tino aren't listed anywhere?

A: Regulatory authorities strongly encourage patients to report any suspected or unexpected side effects they experience. Patients are encouraged to discuss any suspected side effects with a healthcare provider or pharmacist, as they are equipped to report this information to the national drug safety agency.

Q: Can Tino be crushed or split?

A: The oral form of Tino is supplied as film-coated tablets. Unless the patient information leaflet explicitly states that the tablet can be altered, it is generally recommended that it be swallowed whole. The integrity of the film coating may be necessary to ensure proper delivery and absorption, and altering the tablet could impact its intended effectiveness.

Q: Do you have to take Tino at a specific time of day?

A: The official dosing method for the oral tablet specifies that the total daily amount must be administered in divided doses throughout the day. This protocol emphasizes consistent spacing between doses, rather than mandating a specific morning or evening time.

Q: Does Tino affect my ability to drive?

A: Yes, official warnings advise that Tino may affect your ability to drive or operate machinery. This is due to the potential risk of side effects like visual disturbances or dizziness.

Q: Is Tino a daily medication or taken as needed?

A: Tino is approved for short-term, intermittent administration during periods of acute pain or spasm. This means it is typically used as needed to relieve acute symptoms, not as a continuous daily medication.

Q: What is the experience of people who have been on Tino for a long time?

A: Formal clinical trials have had limited follow-up durations, typically spanning only a few days. Therefore, official reports on the long-term outcomes or experiences of people using Tino for extended or repeated periods are limited.

How should Tino be stored and disposed of?

Tino (Tiemonium Methylsulfate) must be stored and disposed of according to specific regulatory requirements to maintain product integrity and ensure environmental safety.

Storage Requirements

Item Official Requirement
Temperature Store below 30 C in a cool, dry place [1.1, 3.3].
Protection Must be protected from light and moisture [1.1, 3.3].
Handling Rule The injection solution must not be frozen [3.4].
Container Keep the product in its original container [3.5].
Child Safety Store the medicine strictly out of the sight and reach of children [1.1].

Disposal Instructions

Disposal of unused or expired Tino must align with regulatory protocols for pharmaceutical waste.

  • Do Not Discard: The product must not be thrown into household trash or poured into the wastewater system (sinks or toilets) [1.3, 2.5].
  • Compliance: All waste material must be disposed of in accordance with local regulatory requirements for pharmaceutical waste [1.6, 2.5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tino found in:

A-Z Index: